All In Biotech

Drug Trial Radar · NCT04187144

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,606

Actual

Start

Apr 23, 2020

Primary completion

Dec 1, 2022

Study completion Dec 1, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.

  • Placebo matching nitrofurantoinDrug

    Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.

  • NitrofurantoinDrug

    Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.

  • Placebo matching gepotidacinDrug

    Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)Time frame: TOC visit (Days 9 to 16)
  2. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S PopulationTime frame: TOC visit (Days 9 to 16)

Locations

113 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Homewood, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Gilbert, Arizona

  • GSK Investigational Site

    Peoria, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Valencia, California

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Apollo Beach, Florida

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Coconut Creek, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Leesburg, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Ormond Beach, Florida

  • GSK Investigational Site

    Palm Springs, Florida

  • GSK Investigational Site

    Pembroke Pines, Florida

  • GSK Investigational Site

    Plant City, Florida

  • GSK Investigational Site

    Sweetwater, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Blackfoot, Idaho

  • GSK Investigational Site

    Boise, Idaho

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    Hanover, Maryland

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Butte, Montana

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    East Orange, New Jersey

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.